MediciNova, Inc. (NASDAQ:MNOV – Get Free Report) saw a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 224,600 shares, a growth of 19.3% from the August 31st total of 188,200 shares. Approximately 0.5% of the company’s stock are short sold. Based on an average daily trading volume, of 39,300 shares, the days-to-cover ratio is presently 5.7 days.
MediciNova Stock Up 9.2 %
MNOV traded up $0.18 during trading hours on Monday, hitting $2.09. 46,308 shares of the company’s stock were exchanged, compared to its average volume of 41,571. The stock’s 50-day moving average is $1.49 and its two-hundred day moving average is $1.43. MediciNova has a 1-year low of $1.12 and a 1-year high of $2.16. The stock has a market cap of $102.26 million, a price-to-earnings ratio of -12.24 and a beta of 0.72.
MediciNova (NASDAQ:MNOV – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, equities research analysts anticipate that MediciNova will post -0.23 EPS for the current year.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on MediciNova
About MediciNova
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Further Reading
- Five stocks we like better than MediciNova
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.
